Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
How should a CAC score of 350 influence risk stratification and preventive strategy intensity in an asymptomatic primary‑prevention patient with borderline‑to‑intermediate ASCVD risk?
Related Questions
When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?
What ECG features for ST depression would prompt you to report these ST changes if a patient exercised well and did not have any questions during their stress test?
Under what clinical circumstances, if any, would you prescribe fenofibrate along with statin therapy?
What are your top takeaways from ACC 2025?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
What advice would you give to patients who are concerned about statin use and its controversies around brain health and dementia risk, based on previous studies?
Is there any indication/benefit for heparin in a patient with suspected type 2 myocardial infarction?
Would you consider PCSK9 inhibitors for patients with elevated coronary calcium score or coronary calcification for primary prevention in lieu of statins/ezetimibe and/or bempedoic acid?
What are your thoughts on the results from the AQUATIC trial which showed that the addition of aspirin daily + oral anticoagulation in patients > 6 months from PCI and with high atherothrombotic risk was associated with a higher risk of death, MI, stroke, coronary revascularization and acute limb ischemia, compared to oral anticoagulation alone?
What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?
